Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 367Ovarian Neoplasms 99Lung Neoplasms 98Neoplasms 84Small Cell Lung Carcinoma 71Breast Neoplasms 59Neoplasm Metastasis 49Triple Negative Breast Neoplasms 46Parkinson Disease 4, Autosomal Dominant Lewy Body 41Fallopian Tube Neoplasms 38Squamous Cell Carcinoma of Head and Neck 33Endometrial Neoplasms 30Carcinoma 30Uterine Cervical Neoplasms 28Colorectal Neoplasms 24Carcinoma, Ovarian Epithelial 23Head and Neck Neoplasms 19Carcinoma, Transitional Cell 18Urinary Bladder Neoplasms 17Advanced Solid Tumors 17Recurrence 15Melanoma 14Stomach Neoplasms 13Peritoneal Neoplasms 13Pancreatic Neoplasms 12Adenocarcinoma 11Lung Diseases 9Glioblastoma 9Carcinoma, Squamous Cell 9Thoracic Neoplasms 8

Interventions

trametinib 2dabrafenib 2Vincristine 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Ganglioneuroma × Carboplatin × Clear all
NCT02684058 2023-12-13

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Novartis

Phase 2 Completed
151 enrolled 45 charts 1 FDA
CNS

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Oligodendroglioma, Ganglioglioma, Neurocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡